• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytodyn Inc (OP:CYDY)

    0.2671 -0.0219 (-7.58%)
    Streaming Delayed Price Updated: 10:42 AM EDT, Mar 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cytodyn Inc

    < Previous 1 2 3 4 Next >
    News headline image
    CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    December 2025 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Resolution of Class Action Lawsuit
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Secures $30 Million Commitment from Yorkville Advisors
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    September 2025 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
    Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health 
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Releases ESMO Breast Cancer Meeting Poster
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    March 2025 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    December 2024 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
    From CytoDyn Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.